Clinical calculator based on clinicopathological characteristics predicts local recurrence and overall survival following radical resection of stage II-III colorectal cancer

被引:0
|
作者
Huang, Fei [1 ]
Wei, Ran [2 ]
Mei, Shiwen [1 ]
Xiao, Tixian [1 ]
Zhao, Wei [1 ]
Zheng, Zhaoxu [1 ]
Liu, Qian [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Colorectal Surg,Canc Hosp, Beijing, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
关键词
colorectal cancer; nomogram; clinical risk factor; prognosis; local recurrence; COLON-CANCER; RECTAL-CANCER; CURATIVE RESECTION; ADJUVANT THERAPY; MANAGEMENT; SURGERY; FLUOROURACIL; PATTERNS; OUTCOMES;
D O I
10.3389/fonc.2025.1494255
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This study aimed to analyze the risk factors and survival prognosis of local recurrence in stage II-III colorectal cancer (CRC) and develop a clinical risk calculator and nomograms to predict local recurrence and survival in treated patients.Methods Patients who underwent radical surgery between January 2009 and December 2019 at the China National Cancer Center were included. Multivariate nomograms and a clinical risk calculator based on Cox regression were developed. Discrimination was measured with an area under curve (AUC) and variability in individual predictions was assessed with calibration curves. We stratified patients into different risk groups according to the established model to predict their prognosis and guide clinical practice.Results The clinical risk calculator incorporated six variables: tumor thrombus, perineural invasion, tumor grade, pathology T-stage, pathology N-stage, and whether more than 12 lymph nodes were harvested. Our clinical risk calculator provided good discrimination, with AUC values of local recurrence-free survival (LRFS) (0.764) and overall survival (OS) (0.815) in the training cohort and LRFS (0.740) and OS (0.730) in the test cohort. Calibration plots illustrated excellent agreement between the clinical risk calculator predictions and actual observations for 3- and 5-year LRFS and OS. Recurrence risk-stratified analysis showed that low-risk patients were more likely to undergo salvage radical surgery when recurrent disease existed.Conclusion The clinical calculator can better account for tumor and patient heterogeneity, providing a more individualized outcome prognostication. The model is expected to aid in treatment planning, such as resectability evaluation, and it can be used in postoperative surveillance (https://oldcoloncancer.shinyapps.io/dynnomapp/).
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Metronomic chemotherapy with tegafur- uracil following radical resection in stage II colorectal cancer
    Chen, Tzu-Chun
    Jeng, Yung-Ming
    Liang, Jin-Tung
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2021, 120 (05) : 1194 - 1201
  • [32] Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction
    Wei, Zhi-Jian
    Qiao, Ya-Ting
    Zhou, Bai-Chuan
    Rankine, Abigail N.
    Zhang, Li-Xiang
    Su, Ye-Zhou
    Xu, A-Man
    Han, Wen-Xiu
    Luo, Pan-Quan
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 14 (08): : 788 - 798
  • [33] Neutrophil to lymphocyte ratio can predict overall survival in patients with stage II to III colorectal cancer
    Cho, Yerim
    Park, Su Bee
    Yoon, Jin Young
    Kwak, Min Seob
    Cha, Jae Myung
    MEDICINE, 2023, 102 (11) : E33279
  • [34] Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)
    Schumacher, Jessica R.
    Neuman, Heather B.
    Yu, Menggang
    Vanness, David J.
    Si, Yajuan
    Burnside, Elizabeth S.
    Ruddy, Kathryn J.
    Partridge, Ann H.
    Schrag, Deborah
    Edge, Stephen B.
    Zhang, Ying
    Jacobs, Elizabeth A.
    Havlena, Jeffrey
    Francescatti, Amanda B.
    Winchester, David P.
    McKellar, Daniel P.
    Spears, Patricia A.
    Kozower, Benjamin D.
    Chang, George J.
    Greenberg, Caprice C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (10): : 1371 - 1379
  • [35] miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer
    Gao, J.
    Li, N.
    Dong, Y.
    Li, S.
    Xu, L.
    Li, X.
    Li, Y.
    Li, Z.
    Ng, S. S.
    Sung, J. J.
    Shen, L.
    Yu, J.
    ONCOGENE, 2015, 34 (31) : 4142 - 4152
  • [36] miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer
    J Gao
    N Li
    Y Dong
    S Li
    L Xu
    X Li
    Y Li
    Z Li
    S S Ng
    J J Sung
    L Shen
    J Yu
    Oncogene, 2015, 34 : 4142 - 4152
  • [37] The significance of involvement of a free serosal surface for recurrence and survival following resection of clinicopathological stage B and C rectal cancer
    Keshava, A.
    Chapuis, P. H.
    Chan, C.
    Lin, B. P. C.
    Bokey, E. L.
    Dent, O. F.
    COLORECTAL DISEASE, 2007, 9 (07) : 609 - 618
  • [38] Erratum to: Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence
    Takuzo Hashimoto
    Michio Itabashi
    Shinpei Ogawa
    Tomoichiro Hirosawa
    Yoshiko Bamba
    Satoru Shimizu
    Shingo Kameoka
    Surgery Today, 2014, 44 : 1791 - 1791
  • [39] A deep learning quantified stroma-immune score to predict survival of patients with stage II-III colorectal cancer
    Xu, Zeyan
    Li, Yong
    Wang, Yingyi
    Zhang, Shenyan
    Huang, Yanqi
    Yao, Su
    Han, Chu
    Pan, Xipeng
    Shi, Zhenwei
    Mao, Yun
    Xu, Yao
    Huang, Xiaomei
    Lin, Huan
    Chen, Xin
    Liang, Changhong
    Li, Zhenhui
    Zhao, Ke
    Zhang, Qingling
    Liu, Zaiyi
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [40] Associations between Post-treatment Inflammatory Biomarkers and Survival among Stage II-III Colorectal Cancer Patients
    Hua, X.
    Kratz, M.
    Newcomb, P. A.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (03) : 691 - 691